¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"nuclear run off assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme-linked immunosorbent assay
    È¿¼Ò°áÇո鿪ÈíÂøÃøÁ¤(¹ý)
  • foam stability assay
    °Åǰ¾ÈÁ¤ÃøÁ¤
  • hemagglutination assay
    Ç÷±¸ÀÀÁý°Ë»ç
  • hemizona assay index
    ¹ÝÅõ¸í¶ìÃøÁ¤ÁöÇ¥
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤(¹ý), ¿ëÇ÷ÇöóÅ©ÃøÁ¤(¹ý)
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤(¹ý), ¸é¿ªÇü±¤°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤, ¸²ÇÁ±¸¼¼Æ÷µ¶¼º°Ë»ç
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤(¹ý), ÇöóÅ©ÃøÁ¤(¹ý)
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • radial partition immunofluorometric assay
    ¹æ»çºÐÇҸ鿪Çü±¤ÃøÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • double-sandwich enzyme-linked immunosorbent assay
    °ãÈ¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme-linked immunosorbent assay
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • foam stability assay
    °Åǰ¾ÈÁ¤ÃøÁ¤
  • focus assay
    ¹ÙÀÌ·¯½ºÆ÷Ä¿½ºÃøÁ¤
  • hemagglutination assay
    Ç÷±¸ÀÀÁýÃøÁ¤(¹ý)
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ©ÃøÁ¤¹ý
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤¹ý, ÇöóÅ©ÃøÁ¤¹ý
  • radial partition immunofluorometric assay
    ¹æ»ç¼ººÐÇҸ鿪Çü±¤ÃøÁ¤
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Euglena assay
    ¿¬µÎ¹ú·¹ÃøÁ¤
  • Falcon assay screening test
    ÆÈÄܺм®¼±º°½ÃÇè
  • IRMA => immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • Jernes plaque assay
    ¿©´Ï ¿ëÇ÷¹ÝÃøÁ¤¹ý, ¿©´Ï ÇöóÅ©ÃøÁ¤¹ý
  • Limulus assay
    ¸®¹°·¯½º ÃøÁ¤¹ý
  • Lowry assay
    ·Î¿ì¸®ÃøÁ¤(¹ý)
  • Raji cell assay
    ¶óÁö¼¼Æ÷½ÃÇè
  • SPA => spermatozoa penetration assay
    Á¤ÀÚ°üÅë½ÃÇè
  • TCD50 assay
    50%Á¾¾çÁ¶Àý¾ç
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • acid phosphatase assay
    »ê¼ºÆ÷½ºÆÄŸÁ¦ ÃøÁ¤
  • ames assay
    ¿¡ÀÓ½ººÐ¼®
  • antibiotic assay
    Ç×»ý¹°Áú ¹ÙÀÌ¿ÀÆò°¡.
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigenic assay
    Ç׿ø¼ººÐ¼®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • off-resonance radiofrequence saturation pulse
    ÀÌÅ» °ø¸í °íÁÖÆÄ Æ÷È­ ÆÞ½º
  • off-resonance signal
    ÀÌÅ» °ø¸í ½ÅÈ£
  • on (and) off effect
    (ÀÚ±Ø)°³½ÃÁ¾·áÈ¿ °ú(ô±Ø°³½ÃÁ¾¿äÈ¿°ú).
  • on (and) off effect
    (ÀÚ±Ø)°³½ÃÁ¾·áÈ¿°ú(ô§Ð½ËÒã·ðûèçüùÍý).
  • on off type
    Á¡¸êÇü(ïÇØþúþ).
  • on-off phenomena
    Á¡¸êÇö»ó(ïÇØþúÞßÚ)
  • on-off-fiber
    °³½ÃÁ¾·áÇü¼¶À¯(ËÒã·ðûèçúþàéë«).
  • point off axis
    ÃàÀÌÅ»ÁöÁ¡
  • pop off valve
    ¹è±â¹ëºê, ¾ÈÀü¹ëºê.
  • shut off valve
    Â÷´Ü¹ëºê.
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • acid phosphatase assay
    »ê¼ºÆ÷½ºÆÄŸÁ¦ ÃøÁ¤
  • ames assay
    ¿¡ÀÓ½ººÐ¼®
  • antibiotic assay
    Ç×»ý¹°Áú ¹ÙÀÌ¿ÀÆò°¡.
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nuclear resonance scattering
    ÇÙ°ø¸íºÐ»ê(ú·ÍìÙ°ÝÂߤ)
  • nuclear zone
    ÇÙ¿ª(ú·æ´)
  • small nuclear RNA
    ¼Ò(á³) ÇÙ(ú·)RNA
  • small nuclear ribonucleoprotein
    ¼Ò(á³) ÇÙ(ú·) ¶óÀ̺¸ÇÙ»ê´Ü¹éÁú(ú·ß«Ó±ÛÜòõ)
  • assay
    ¾Æ½êÀÌ
  • binding assay
    °áÇÕ(Ì¿ùê)¾Æ½êÀÌ
  • biological assay
    »ý¹°ÇÐÀû(ßæÚªùÊîÜ) ¾Æ½êÀÌ
  • competitive radioligand assay
    °æÇÕÀû(ÌæùêîÜ ¹æ»ç´É(Û¯ÞÒÒö)¸®°£µå ¾Æ½êÀÌ
  • continuous assay
    ¿¬¼Ó(Ö§áÙ)¾Æ½êÀÌ
  • coupled assay
    °ø¿ª(Íìæµ) ¾Æ¼¼ÀÌ (ÔÒ) auxiliary enzyme
  • d-assay
    d-¾Æ½êÀÌ
  • discontinuous assay
    ºÒ¿¬¼Ó(ÝÕææáÙ) ¾Æ½êÀÌ
  • dot blot assay
    Á¡(ïÃ)ºí·Ô ¾Æ¼¼ÀÌ
  • enzyme assay
    È¿¼Ò(ý£áÈ)¾Æ½êÀÌ
  • enzyme-linked immunosorbent assay
    È¿¼Ò¿¬°ü ¸é¿ªÈíÂø (ý£áÈ֤μØóæ¹ýåó·) ¾Æ½êÀÌ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nuclear division
    ¡ì¼¼Æ÷¡íÇٺп­
  • nuclear energy
    ÇÙ¿¡³ÊÁö
  • nuclear induction
    ÇÙÀ¯µµ
  • nuclear magnetic resonance [=NMR]
    ÇÙÀÚ±â°ø¸í
  • nuclear medicine
    ÇÙÀÇÇÐ
  • nuclear paramagnetic resonance
    ÇÙ»óÀÚ¼º°ø¸í
  • nuclear paramagnetism
    ÇÙ»óÀÚ¼º
  • nuclear power
    ÇÙ·Â
  • nuclear spin
    ÇÙ½ºÇÉ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HISKEW Health Information Skeletonized Eligibility Write-off [file, Medicare]
Off official
O&O on and off
TTO time trade-off [method]
NM near-miss; neomycin; neuromedin; neuromuscular; neutrophil migration; nictitating membrane; nitrogen...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TTO Time Trade OFF
MWCO molecular weight cut-off
nuclear VV nuclear volume
SPRIA Solid Phase Radioimmune Assay
ELISA Enzyme Linked Immuno Sorbant Assay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • enzyme-linked immunoadsorbent assay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
  • enzyme-linked immunosorbent assay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
  • hemolytic plaque assay
    ¿ëÇ÷¹Ý ½ÃÇè, ¿ëÇ÷¹Ý ÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ© ÃøÁ¤¹ý
  • human zona binding assay
    »ç¶÷ Á¤ÀÚ Åõ¸í´ë ºÎÂø °Ë»ç
  • microbiological assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • micrologica assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • radioreceptor assay
    ¹æ»ç¼± ¼ö¿ëü ÃøÁ¤¹ý
    ÀÏÁ¾ÀÇ ¹æ»ç Ç¥Áö °ËÁ¤¹ýÀ¸·Î¼­, Á¶Á÷ Ç¥º» ³»¿¡ Àִ ȣ¸£¸ó¿¡ ´ëÇØ Ư¼öÇÑ ¼¼Æ÷ ¼ö¿ëüÀÇ ³óµµ¸¦ ¹æ»ç Ç¥ÁöÇÑ È£¸£¸óÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÏ´Â °Í.
  • free nuclear division
    À¯¸® ÇÙ ºÐ¿­
    ¼¼Æ÷Áúü ºÐ¿­À» ¼ö¹ÝÇÏÁö ¾Ê°í ÀÌ·ç¾îÁö´Â ÇÙ ºÐ¿­. ÀÚÀ¯ ÇÙ ºÐ¿­À̶ó°íµµ ÇÑ´Ù. À¯¸® ÇÙ ºÐ¿­ °á°ú ÀϽÃÀûÀ¸·Î ´ÙÇÙ ¼¼Æ÷°¡ Çü¼ºµÇÁö¸¸, ±× ÈÄ µ¿½Ã¿¡ ÇÙ »çÀÌ °Ýº®ÀÌ Çü¼ºµÇ¾î ´Ù¼öÀÇ ¼¼Æ÷·Î ºÐ¸®µÈ´Ù. °Ñ¾¾½Ä¹°ÀÇ ¹è Çü¼º, Á¾ÀÚ ½Ä¹°ÀÇ ¹èÁ¥ Çü¼º, °üÁ¶·ùÀÇ ¿µ¾çü µî¿¡¼­ º¼ ¼ö ÀÖ´Ù. °ïÃæÀÇ ³­ÇÒ ÃʱâÀÇ °úÁ¤µµ À̰Ϳ¡ ÇØ´çÇÑ´Ù.
  • net nuclear magnetization
    ÃÑ ÇÙ ÀÚ±âÈ­
  • nuclear
    ÇÙÀÇ, ¿øÀÚ ÇÙÀÇ
  • nuclear antigen
    ÇÙ Ç׿ø
  • nuclear bag fiber
    ÇÙ ³¶ ¼¶À¯
  • nuclear bombardment
    ÇÙ Ãæµ¹
  • nuclear cataract
    ÇÙ ¹é³»Àå
  • nuclear charge
    ÇÙ ÇÏÀü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
on-off phenomenon A state in the treatment of Parkinson's disease by l-dopa, in which there is a rapid fluctuation of akinetic (off) and choreoathetotic (on) movements.
(05 Mar 2000)
ordered on-random off mechanism A scheme for substrate binding and product release for multisubstrate enzymes; for a two-substrate two-product enzyme with this mechanism, the individuals have to bind to the enzyme in a distinct order; however, once the products are formed they may dissociate from the enzyme in either order. It has been suggested that pyruvate kinase has such a mechanism. The random on-ordered off mechanism is simply the reverse of this mechanism.
(05 Mar 2000)
acetyl reduction assay <investigation> A technique for measuring the nitrogen fixation activity in photosynthetic organisms. It uses a flame ionisation detector and a gas chromatography apparatus to determine the reduction of acetylene to ethylene by the enzyme nitrogenase.
(06 May 1997)
Ames assay <procedure> One of a number of procedures used to test substances for likely ability to cause cancer that combines the use of animal tissue to generate active metabolites of the substance with a test for mutagenicity in bacteria.
(18 Nov 1997)
antibiotic assay <investigation> A test to determine how sensitive a bacterial or fungal strain is to arange of antibiotics bymeasuring the microbes' ability to grow in astandard dilution of each chemical.
(09 Oct 1997)
assay <procedure> The determination of the amount of a particular constituent of a mixture or of the biological or pharmacological potency of a drug.
(10 May 1997)
bandshift assay <investigation> An assay for proteins, such as transcription factors, that bind specific DNA sequences.
A labelled oligonucleotide corresponding to the recognition sequence is incubated with an appropriate nuclear protein extract and run on a nondenaturing acrylamide gel. Oligonucleotides that have been bound by proteins are retarded relative to those that are unbound.
(18 Nov 1997)
biological assay <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity.
It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein.
(21 Mar 1998)
radioimmunoprecipitation assay Sensitive assay using radiolabelled antigens to detect specific antibodies in serum. The antigens are allowed to react with the serum and then precipitated using a special reagent such as protein a sepharose beads. The bound radiolabelled immunoprecipitate is then commonly analyzed by gel electrophoresis. Radioimmunoprecipitation assay (ripa) is often used as a confirmatory test for diagnosing the presence of HIV antibodies.
(12 Dec 1998)
radioligand assay <radiobiology> Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labelled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).
(12 Dec 1998)
radioreceptor assay A competitive binding assay in which the binder is a membrane or tissue receptor rather than an antibody.
(05 Mar 2000)
Raji cell radioimmune assay For immune complexes; a procedure by which immune complexes adsorbed from a test serum by a standard preparation of lymphoblastoid (Raji) cells are assayed by the capacity to bind 125I-labelled antibody to immunoglobulin.
(05 Mar 2000)
gel retardation assay A lab technique used to find out if there are proteins binding a fragment of DNA (in a DNA-protein complex) by watching how fast the DNA fragment moves through an electric field and seeing whether it moves slower when a particular protein is also present.
(09 Oct 1997)
checkerboard assay <procedure> Variant of the Boyden chamber assay for leucocyte chemotaxis introduced by Zigmond. By testing different concentrations of putative chemotactic factor in nongradient conditions, it is possible to calculate the enhancement of movement expected due simply to chemokinesis and to compare this with the distances moved in positive and negative gradients. Good experimental design thus allows chemotaxis to be distinguished from chemokinesis.
(21 May 1997)
chloramphenicol acetyltransferase assay <investigation> A lab technique used to determine whether a given fragment of DNA has a promoter on it to encourage transcription to occur, by attaching the gene (called the CAT gene) which codes for the CAT enzyme to it, and observing whether the CAT enzyme is produced.
(05 Jan 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nuclear fusion
    ÇÙÀ¶ÇÕ
  • nuclear grapeshot
    (±º)¼ÒÇü Àü¼úÇÙ¹«±â
  • nuclear magnetic resonance
    (¹°)ÇÙÀڱ⠰ø¸í
  • nuclear medicine
    (ÀÇ)ÇÙÀÇÇÐ(¹æ»ç¼± ÇÙÁ¾À» ÀÌ¿ëÇÏ´Â ÀÓ»óÀÇÇÐ)
  • nuclear membrane
    (»ý)ÇÙ¸·
  • nuclear molecule
    (¹°)¿øÀÚÇÙ ºÐÀÚ
  • nuclear nonproliferation
    ÇÙÈ®»ê ¹æÁö
  • nuclear physicist
    ¿øÀÚ ¹°¸®ÇÐÀÚ
  • nuclear physics
    (¿øÀÚ)ÇÙ ¹°¸®ÇÐ
  • nuclear plant
    ¿øÀÚ·Â ¹ßÀü¼Ò
  • nuclear power
    (µ¿·ÂÀ¸·Î¼­ÀÇ)¿øÀÚ·Â;ÇÙ¹«±â º¸À¯±¹
  • nuclear powered
    ¿øÀÚ·ÂÀ» µ¿·ÂÀ¸·Î ÇÏ´Â(Àá¼öÇÔµî)
  • nuclear reaction
    ÇÙ¹ÝÀÀ
  • nuclear reactor
    ¿øÀÚ·Î
  • nuclear resonance
    ÇÙ°ø¸í
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á